Citation Impact
Citing Papers
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Progress and challenges towards targeted delivery of cancer therapeutics
2018 Standout
Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug
2015
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2017 Standout
Breast cancer
2019 Standout
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
2011
Hierarchical Mechanisms for Direct Reprogramming of Fibroblasts to Neurons
2013 StandoutNobel
Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer
2013
Dissecting the Heterogeneity of Triple-Negative Breast Cancer
2012
Triple-Negative Breast Cancer: An Unmet Medical Need
2011
Triple-negative breast cancer molecular subtyping and treatment progress
2020 Standout
Triple-Negative Breast Cancer
2010 Standout
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
2018 Standout
The molecular hallmarks of epigenetic control
2016 Standout
Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor
2014 StandoutNobel
The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade
2009
Breast cancer
2016 Standout
A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)
2014
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1
2008 Standout
Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial–mesenchymal transition
2007
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013 Standout
DAF-16 employs the chromatin remodeller SWI/SNF to promote stress resistance and longevity
2013 StandoutNobel
Appraising iniparib, the PARP inhibitor that never was—what must we learn?
2013
Migrastatin analogues target fascin to block tumour metastasis
2010 Nature
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer
2007
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Modulation of oxidative stress as an anticancer strategy
2013 Standout
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Triple-negative breast cancer: treatment challenges and solutions
2016
Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – Results from the prospective German TMK cohort study
2017
A clinically relevant gene signature in triple negative and basal-like breast cancer
2011
Proteomic maps of breast cancer subtypes
2016
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
2011
Histological and molecular types of breast cancer: is there a unifying taxonomy?
2009
Cancer-associated cachexia
2018 Standout
The Perseus computational platform for comprehensive analysis of (prote)omics data
2016 Standout
Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer
2016
Drug repurposing: progress, challenges and recommendations
2018 Standout
Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance
2011
Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease
2015
Pioneer transcription factors: establishing competence for gene expression
2011
On the Dependency of Cellular Protein Levels on mRNA Abundance
2016 Standout
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
2018
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery
2012 Standout
Sarcopenia
2019 Standout
Guidance of regulatory T cell development by Satb1-dependent super-enhancer establishment
2016 StandoutNobel
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Gene-Expression Signatures in Breast Cancer
2009
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Male breast cancer: a disease distinct from female breast cancer
2018
A review of estrogen receptor/androgen receptor genomics in male breast cancer
2017
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
2013 Standout
ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients
2018
A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study
2012
Therapeutic potential of PARP inhibitors for metastatic breast cancer
2011
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012 Standout
Clonal evolution in cancer
2012 StandoutNature
An “elite hacker”
2012
Diagnosing the decline in pharmaceutical R&D efficiency
2012 Standout
CLOCK:BMAL1 is a pioneer-like transcription factor
2014 StandoutNobel
Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy
2007
Subtyping of triple‐negative breast cancer: Implications for therapy
2014
The side effects of platinum-based chemotherapy drugs: a review for chemists
2018 Standout
Nanoparticle albumin-bound (nab™)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer
2010
Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies
2017
Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer
2014
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
2014 Standout
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
2018
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Computationally designed peptide macrocycle inhibitors of New Delhi metallo-β-lactamase 1
2021 StandoutNobel
Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
2016
Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer
2009
The sva package for removing batch effects and other unwanted variation in high-throughput experiments
2012 Standout
Cancer Genome Landscapes
2013 StandoutScience
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
2014 Standout
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Independent surrogate variable analysis to deconvolve confounding factors in large-scale microarray profiling studies
2011
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
Metastatic Behavior of Breast Cancer Subtypes
2010 Standout
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Clinical Translation of Nanomedicine
2015
Works of Michael Danso being referenced
Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
2014
Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel With Carboplatin and Trastuzumab as First-line Therapy for Women With HER2-Overexpressing Metastatic Breast Cancer
2010
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
2017
An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen
2006
Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple-negative breast cancer (TNBC): Hoosier Oncology Group BRE09-146.
2014
A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).
2011
Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer
2008
Abstract P2-08-04: Phase 1/2 study of oral seviteronel (VT-464), a dual CYP17-lyase inhibitor and androgen receptor (AR) antagonist, in patients with advanced AR positive triple negative (TNBC) or estrogen receptor (ER) positive breast cancer (BC)
2017
Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
2014
Phase II study of weekly nanoparticle paclitaxel (ABI-007), carboplatin and trastuzumab as first-line therapy of HER2-positive metastatic breast cancer
2006